Mesenchymal Stem Cell-Derived Microvesicles Protect Against Acute Tubular Injury

Department of Internal Medicine, Research Center for Experimental Medicine, University of Torino, Torino, Italy.
Journal of the American Society of Nephrology (Impact Factor: 9.47). 05/2009; 20(5):1053-67. DOI: 10.1681/ASN.2008070798
Source: PubMed

ABSTRACT Administration of mesenchymal stem cells (MSCs) improves the recovery from acute kidney injury (AKI). The mechanism may involve paracrine factors promoting proliferation of surviving intrinsic epithelial cells, but these factors remain unknown. In the current study, we found that microvesicles derived from human bone marrow MSCs stimulated proliferation in vitro and conferred resistance of tubular epithelial cells to apoptosis. The biologic action of microvesicles required their CD44- and beta1-integrin-dependent incorporation into tubular cells. In vivo, microvesicles accelerated the morphologic and functional recovery of glycerol-induced AKI in SCID mice by inducing proliferation of tubular cells. The effect of microvesicles on the recovery of AKI was similar to the effect of human MSCs. RNase abolished the aforementioned effects of microvesicles in vitro and in vivo, suggesting RNA-dependent biologic effects. Microarray analysis and quantitative real time PCR of microvesicle-RNA extracts indicate that microvesicles shuttle a specific subset of cellular mRNA, such as mRNAs associated with the mesenchymal phenotype and with control of transcription, proliferation, and immunoregulation. These results suggest that microvesicles derived from MSCs may activate a proliferative program in surviving tubular cells after injury via a horizontal transfer of mRNA.

  • Source
    • "The therapeutic role of the MSC secretome has also been reported in a preclinical model of acute renal failure through downregulation of pro-inflammatory molecules such as IL-1b, TNF-a, interferon-g and inducible nitric oxide synthase in treated kidneys and concurrent induction of the anti-inflammatory cytokines IL-10, basic fibroblast growth factor, and TGF-a [180]. Additionally, therapeutic effects of adult MSC-derived microvesicles (MVs) was confirmed in a rat model of acute kidney injury through mRNA transfer, leading to induction of epigenetic changes in the resident host cells, cell cycle restoration and activation of tissue-regenerative programs [181]. Immediate injection of MVs obtained from adult MSC after ischemia and reperfusion injury could prevent both acute and chronic kidney disease [182]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cancer treatment plans mainly include chemotherapy, radiotherapy and surgery, which exert serious adverse reactions immediately or during the long term after cancer therapy in many patients. In several cases, treatment-related adverse effects outweigh treatment benefits and worsen the patient's condition. This problem is not avoidable with current cancer therapy procedures; therefore, improved understanding and earlier prevention and reversion of treatment-related complications are particularly important before the lesions become progressive and irreversible. Mesenchymal stromal cell therapy is very promising in recent clinical research and investigations. Their potential properties such as regenerative and reparative functions and anti-inflammatory activity make them proper candidates for cell therapy to recover cancer patients from treatment-related adverse effects or may even prevent them. This article discuss benefits of applying human mesenchymal stromal cell therapy after current cancer treatment plans, with the purpose of prevention and healing of adverse reactions, faster patient recovery after radio/chemotherapy, reducing rates of treatment failure and cancer recurrence and increasing patient quality of life after treatment cessation.
    Cytotherapy 01/2015; 17(5). DOI:10.1016/j.jcyt.2014.10.015 · 3.10 Impact Factor
  • Source
    • "Mesenchymal stromal cell-EVs also contain nucleic acids (mRNA and non-coding RNA). The mRNAs present in EVs are representative of the multiple differentiation and functional properties of MSCs, including transcripts related to several different cell functions (e.g., the control of transcription, cell proliferation, and immune regulation) (33). EVs from MSCs also contain mRNA for receptors of specific growth factors, such as mRNA for the insulin growth factor 1 (IGF-1) receptor (34). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Extracellular vesicles (EVs) are membrane vesicles, which are secreted by a variety of cells that have a relevant role in intercellular communication. EVs derived from various cell types exert different effects on target cells. Mesenchymal stromal cells (MSCs) are stem cells that are ubiquitously present in different tissues of the human body, and MSC-derived EVs take part in a wide range of biological processes. Of particular relevance is the effect of MSCs on tumor growth and progression. MSCs have opposing effects on tumor growth, being able either to favor angiogenesis and tumor initiation, or to inhibit progression of established tumors, according to the conditions. Different studies have reported that EVs from MSCs may exert either an anti- or a pro-tumor growth effect depending on tumor type and stage of development. In this review, we will discuss the data presented in the literature on EV-mediated interactions between MSCs and tumors.
    Frontiers in Immunology 08/2014; 5:382. DOI:10.3389/fimmu.2014.00382
  • Source
    • "In addition, because transplanted MSCs were found in the lung parenchyma instead of the walls of pulmonary vessels, the paracrine effects of MSCs should be responsible for the role of MSCs in pulmonary remodeling. Indeed, the paracrine mechanism has been proposed to be one of the underlying mechanisms that contributes to the therapeutic effect of transplanted stem cells7,8,22. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Aim: Microvesicles (MVs) are nanoscale membrane fragments released from virtually all cell types upon activation or apoptosis, and may contribute to the beneficial effects of stem cell therapy. In this study, we investigated the therapeutic effects of mesenchymal stem cell (MSC) derived MVs (MSC-MVs) on pulmonary artery hypertension (PAH) in rats. Methods: MSC-MVs were isolated from rat bone marrow MSCs that were cultured in a serum-free conditioned medium. Transmission electron microscopy (TEM), flow cytometry and nanoparticle tracking analysis (NTA) were used to characterize the MVs. Adult SD rats were injected with monocrotaline (50 mg/kg, sc) to induce PAH. Three weeks later, the rats were intravenously injected with MSCs, MSC-MVs or saline for 2 weeks. At the end of treatments, the hemodynamic parameters and pathological right ventricular and pulmonary arterial remodeling were analyzed in each group. Results: The MSC-MVs showed general morphologic characteristics of MVs and expressed annexin V and CD29 markers under TEM, and their size ranged from 40 to 300 nm. Intravenous injection of MSC-MVs or MSCs significantly ameliorated the mean pulmonary artery pressure (mPAP) and mean right ventricle pressure (mRVP) in PAH rats. Furthermore, intravenous injection of MSC-MVs or MSCs significantly decreased the right ventricle (RV) hypertrophy and pulmonary arteriole area index (AI) and thickness index (TI) in PAH rats. Conclusion: Intravenous injection of MSC-MVs or MSCs produces similar beneficial effects for treating PAH, and our results provide a basis for cell-free approach in stem cell therapy.
    Acta Pharmacologica Sinica 08/2014; 35(9). DOI:10.1038/aps.2014.61 · 2.50 Impact Factor
Show more